In particular, developments in stem cell science like cellular reprogramming revealed new strategies for approaching previously formidable technical barriers like producing human cells in states and numbers sufficient for effective research and biomedical development. However, despite the remarkable increase in technologies and knowledge, patients are still waiting for new approved, effective treatments based on stem cells and their promise.
There are now many more new stem cell treatment concepts in various orbits about the long-standing stem cell medicine standard, hematopoietic stem cell (HSC) transplantation therapy. Whereas some new concepts emulate the HSC standard, others are a distinct departure from it. Those that model the standard still often face distinctive biological and physiological barriers (e.g., difficulty accessing treatment compartments); and those that depart are often lured away because of distinct practical advantages (e.g., convenient cell sourcing). Therefore, most have one or more limitations or problems that may compromise their efficacy. Even treatment strategies enabled by the tremendous advance of cellular reprogramming technology are limited by the tumorigenicity of reprogrammed cells; and the related genomic and epigenomic mutations of reprogrammed stem cells may also compromise the function of their derivative cells in drug development applications.
So, the past decade’s seemingly accelerated path to success in stem cell medicine is, in fact, cluttered with blocking problems – some preexisting and some introduced by the enabling technologies themselves – that must be cleared before stem cell medicine can realize its promise. The Zing Conference on “Challenges, Solutions, and Progress in Stem Cell Medicine” has the aim of facilitating a reduction in these blocking problems by offering leading practitioners, across the many disciplines of the stem cell medicine field, a unique forum for integrated group dialogue on the main issues limiting better progress in stem cell medicine and on devising solutions.
Conference Topics AddressedI. Introduction to Stem Cell Medical ApplicationsTransplantation Medicine
Disease research models
Drug development applications
Cosmetics
Veterinary
II. Stem Cell Medicine Challenges and Solutions
Sourcing stem cells
Therapeutic stem cell biomanufacturing
Quantitative biomarkers for tissue stem cells
Stem cell tissue engineering
Tumorigenicity
Differentiating stem cells
Genomic and epigenomic mutation
Immunity barriers
Tissue niche delivery
Treatment longevity
Tissue stem cell toxicologyIII. Stem Cell Medicine: State of the ScienceTissue stem cells
Pluripotent stem cells
Other stem cell types (e.g., placental)
Homologous stem cell transplantation research
Heterologous stem cell transplantation research
Stem cell genetic engineering (e.g., CRISPR/Cas9 technology application)
IV. Stem Cell Medicine: State of the Clinic
The standard: advances in HSC transplantation medicine
New stem cell transplantation concepts
Homologous stem cell transplantation clinical trials
Heterologous stem cell transplantation clinical trials
Stem cell gene therapy clinical trials
There are now many more new stem cell treatment concepts in various orbits about the long-standing stem cell medicine standard, hematopoietic stem cell (HSC) transplantation therapy. Whereas some new concepts emulate the HSC standard, others are a distinct departure from it. Those that model the standard still often face distinctive biological and physiological barriers (e.g., difficulty accessing treatment compartments); and those that depart are often lured away because of distinct practical advantages (e.g., convenient cell sourcing). Therefore, most have one or more limitations or problems that may compromise their efficacy. Even treatment strategies enabled by the tremendous advance of cellular reprogramming technology are limited by the tumorigenicity of reprogrammed cells; and the related genomic and epigenomic mutations of reprogrammed stem cells may also compromise the function of their derivative cells in drug development applications.
So, the past decade’s seemingly accelerated path to success in stem cell medicine is, in fact, cluttered with blocking problems – some preexisting and some introduced by the enabling technologies themselves – that must be cleared before stem cell medicine can realize its promise. The Zing Conference on “Challenges, Solutions, and Progress in Stem Cell Medicine” has the aim of facilitating a reduction in these blocking problems by offering leading practitioners, across the many disciplines of the stem cell medicine field, a unique forum for integrated group dialogue on the main issues limiting better progress in stem cell medicine and on devising solutions.
Conference Topics AddressedI. Introduction to Stem Cell Medical ApplicationsTransplantation Medicine
Disease research models
Drug development applications
Cosmetics
Veterinary
II. Stem Cell Medicine Challenges and Solutions
Sourcing stem cells
Therapeutic stem cell biomanufacturing
Quantitative biomarkers for tissue stem cells
Stem cell tissue engineering
Tumorigenicity
Differentiating stem cells
Genomic and epigenomic mutation
Immunity barriers
Tissue niche delivery
Treatment longevity
Tissue stem cell toxicologyIII. Stem Cell Medicine: State of the ScienceTissue stem cells
Pluripotent stem cells
Other stem cell types (e.g., placental)
Homologous stem cell transplantation research
Heterologous stem cell transplantation research
Stem cell genetic engineering (e.g., CRISPR/Cas9 technology application)
IV. Stem Cell Medicine: State of the Clinic
The standard: advances in HSC transplantation medicine
New stem cell transplantation concepts
Homologous stem cell transplantation clinical trials
Heterologous stem cell transplantation clinical trials
Stem cell gene therapy clinical trials
